Michael Grass, PhD, is is head of Solid Form Services at Lonza Pharma & Biotech and was previously principal scientist at Capsugel’s Bend, Oregon facility.
Innovative approaches to drug screening—such as evaluation to identify the optimal solid state of a molecule and in-vitro characterization to establish the optimal solid state of a molecule and the ideal bioavailability-enhancing technology—can help drug developers meet accelerated development timelines while managing risk.
Model-based formulation and technology selection methodologies facilitate rapid product development.
Published: September 2nd 2020 | Updated:
Published: November 2nd 2017 | Updated:
